# EDGAR Filing Document

**Accession Number:** 0001973705
**File Stem:** 0001193125-26-176222
**Filing Date:** 2026-4
**Character Count:** 7404
**Document Hash:** e1e0ce286e6655f2ac14cd642520c5e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-176222.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001193125-26-176222

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260422

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lesage Anne
- **CENTRAL INDEX KEY:** 0001973705

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40010
- **FILM NUMBER:** 26891666

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O PHARVARIS N.V.
- **STREET 2:** EMMY NOETHERWEG 2
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **ZIP:** 2333 BK
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharvaris N.V.
- **CENTRAL INDEX KEY:** 0001830487
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31 (0)71 203 6410

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharvaris, B.V.
- **DATE OF NAME CHANGE:** 20201029

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lesage Anne<br><sub>(Last) (First) (Middle)</sub><br>1 CRANBERRY HILL SUITE 400<br><sub>(Street)</sub><br>LEXINGTON, MA 02421<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Early Development_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Pharvaris N.V. [ PHVS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-04-22 |  | M<sup>(1)</sup> |  | 500 | A | $2.59 | 56950 | D |  |
| Common Stock | 2026-04-22 |  | S<sup>(1)</sup> |  | 500 | D | $30 | 56450 | D |  |
| Common Stock | 2026-04-22 |  | M<sup>(1)</sup> |  | 7000 | A | $8.05 | 63450 | D |  |
| Common Stock | 2026-04-22 |  | S<sup>(1)</sup> |  | 7000 | D | 30.0517<sup>(2)</sup> | 56450 | D |  |
| Common Stock | 2026-04-22 |  | S |  | 7000 | D | 30.0511<sup>(2)</sup> | 156969 | I | GrayMatters Consulting B.V. |
| Common Stock | 2026-04-23 |  | S |  | 100 | D | $30.0300 | 156869 | I | GrayMatters Consulting B.V. |
| Common Stock | 2026-04-23 |  | M<sup>(1)</sup> |  | 100 | A | $2.59 | 56550 | D |  |
| Common Stock | 2026-04-23 |  | S<sup>(1)</sup> |  | 100 | D | 30.0300<sup>(3)</sup> | 56450 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $2.59 | 2026-04-22 |  | M<sup>(1)</sup> |  |  | 500 | <sup>(4)</sup> | 2030-01-01 | Common Stock | 500 | $0 | 15972 | D |  |
| Stock Option (Right to Buy) | $8.05 | 2026-04-22 |  | M<sup>(1)</sup> |  |  | 7000 | <sup>(5)</sup> | 2031-02-05 | Common Stock | 7000 | $0 | 113000 | D |  |
| Stock Option (Right to Buy) | $2.59 | 2026-04-23 |  | M<sup>(1)</sup> |  |  | 100 | <sup>(4)</sup> | 2030-01-01 | Common Stock | 100 | $0 | 15872 | D |  |

---

### Footnotes:

(1) This is a scheduled exercise and sale from 10b5-1 trading plan.

(2) These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13.

(3) These shares were sold in multiple transactions at prices ranging from $30.03 to $31.03.

(4) 25% of the option vested on January 1, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter.

(5) 25% of the option vested on February 5, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

**Signature:** /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage  
**Date:** 2026-04-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**